Castle Biosciences reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field ...

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference ...

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...

Castle Biosciences will celebrate the grand opening of its headquarters in Friendswood on March 24, according to a March 6 news release from the company.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of ...

The Phase 2a study results revealed that VIS-101 produced rapid and durable treatment responses with both 3 mg and 6 mg dose cohorts in patients with wet age-related macular degeneration (wet AMD).

The John Shufeldt School of Medicine and Medical Engineering will combine clinical medicine with biomedical science and ...